Publication details

Role zánětu v etiopatogenezi farmakorezistentní epilepsie a refrakterního status epilepticus.

Title in English The role of inflammation in etiopathogenesis of pharmacoresistant epilepsy and refractory status epilepticus
Authors

AULICKÁ Štefánia ČESKÁ Katarína ŠÁNA Jiří LOJA Tomáš JABANDŽIEV Petr PAPEŽ Jan DANHOFER Pavlína VINOHRADSKÁ Hana DOLEŽALOVÁ Irena BRÁZDIL Milan ŠTOURAČ Petr OŠLEJŠKOVÁ Hana SLABÝ Ondřej

Year of publication 2020
Type Article in Periodical
Magazine / Source Česká a slovenská neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.14735/amcsnn20208
Doi http://dx.doi.org/10.14735/amcsnn20208
Keywords pharmacoresistant epilepsy; refractory status epilepticus; cytokines; chemokines; polymorphisms
Description Brain inflammation represents a common substrate of pharmacoresistant epilepsy of different etiologies and it can directly affect neuronal excitability. Neuromodulatory properties of some proinflammatory molecules (cytokines, chemokines) may be responsible for hyperexcitability in neuronal networks. The relation between inflammation and epilepsy is reciprocal. The inflammatory processes in the brain may participate in initiating seizure activity and simultaneously they may be a consequence of the recurrence of the seizures. Pharmacological studies on experimental models focused on IL-1 beta/IL-1R1, HMGB1/TLR4 and COX-2/prostaglandin systems demostrate that these inflammatory pathways significantly in triggering and recurring seizure activity. Status epilepticus (SE) leads to development of inflammatory processes which can be detected in brain tissue, cerebrospinal fluid and blood serum. Prolonged seizures and SE lead to fast and prolonged activation of specific inflammatory pathways in brain areas accordant with the epileptogenic zone. Understanding the complex role of inflammation in the generation and exacerbation of epilepsy and development of pharmacoresistance in epilepsy is crucial for the identification of new molecular targets for therapeutic intervention in these patients.